News Sentiment

CLPT sentiment intelligence

Clearpoint Neuro Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 72 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 17.50 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 61

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-6.5% over one week, +30.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

EpilepsyGTx Taps ClearPoint Neuro for EPY201 Clinical Trial Delivery

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -6.5% Price reacting lower
Trend fit Trend active 30.2% over four weeks
Fair value 58.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 50
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 61
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 11
TradingView 7
Moomoo 4
Seeking Alpha 2
Stock Traders Daily 2
Investing.com Nigeria 2
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 24
Analyst action 2
Deals and strategy 2
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 72
Contract Pharma Direct company coverage

EpilepsyGTx Taps ClearPoint Neuro for EPY201 Clinical Trial Delivery

EpilepsyGTx has partnered with ClearPoint Neuro to deliver its lead gene therapy candidate, EPY201, for focal refractory epilepsy (FRE) in an upcoming Phase 1/2a clinical trial. EpilepsyGTx will utilize ClearPoint's SmartFlow Cannula and Neuro Navigation system for precise, MRI-g

Tone
Positive 74/100
Event
Market update
Published
14 Jul 2026 13:45
Source
Contract Pharma
Stock Traders Daily Direct company coverage

(CLPT) Risk Channels and Responsive Allocation

The article analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT) highlighting conflicting sentiment across different time horizons and an oscillation pattern. It identifies an exceptional 101.8:1 risk-reward short setup and outlines three AI-generated trading strategies for various ris

Tone
Negative 41/100
Event
Market update
Published
11 Jul 2026 01:39
Source
Stock Traders Daily
Investing.com Nigeria Direct company coverage

Form 4 Clearpoint Neuro Inc For: 6 July By Investing.com

This article reports on a Form 4 filing for Clearpoint Neuro Inc. (CLPT) for July 6. The company's stock symbol is CLPT, and its price performance is noted as +3.41%. The news brief does not provide further details regarding the content of the Form 4.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 01:26
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Director at ClearPoint Neuro (NASDAQ: CLPT) receives 222-share stock grant

ClearPoint Neuro Director Timothy T. Richards was granted 222 shares of Common Stock as compensation for fees under the company's Non-Employee Director Compensation Plan. The shares, valued at $17.84 each, were issued on June 30, 2026, and bring Richards' direct holdings to 87,54

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 00:08
Source
Stock Titan
Finviz Direct company coverage

CLPT - ClearPoint Neuro Inc Volatility & Greeks

This article provides a detailed financial overview of ClearPoint Neuro Inc (CLPT), including its stock performance, key financial metrics, and volatility indicators. It lists various financial ratios, employee and ownership data, and price performance over different periods. The

Tone
Positive 61/100
Event
Market update
Published
04 Jul 2026 11:40
Source
Finviz
Investing.com Canada Direct company coverage

Form 4 Clearpoint Neuro Inc For: 2 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Clearpoint Neuro Inc., dated July 2nd. It provides key financial data including market indices, commodity prices, and stock performances for various companies like Clearpoint Neuro (CLPT).

Tone
Neutral 50/100
Event
Macro sensitivity
Published
02 Jul 2026 20:40
Source
Investing.com Canada
Stock Titan Direct company coverage

ClearPoint Neuro (CLPT) CFO acquires 1,085 shares through ESPP

ClearPoint Neuro's Chief Financial Officer, Danilo D'Alessandro, acquired 1,085 shares of the company's common stock through an Employee Stock Purchase Plan (ESPP). The shares were purchased at $11.93 each for the period spanning January 1 to June 30, 2026. Following this transac

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

ClearPoint Neuro (CLPT) CBO adds 1,781 ESPP shares, now holds 110,263

ClearPoint Neuro, Inc.'s Chief Business Officer, L. Jeremy Stigall, acquired 1,781 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at $11.93 per share. This transaction, covering the period from January 1, 2026, to June 30, 2026, brings his direct

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

ClearPoint Neuro (CLPT) CEO acquires 1,361 ESPP shares in Form 4

ClearPoint Neuro, Inc. CEO and President Joseph Burnett acquired 1,361 shares of company common stock through an Employee Stock Purchase Plan (ESPP) on June 30, 2026, at $11.93 per share. This purchase, covering the period from January 1 to June 30, 2026, was made at a discount.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:40
Source
Stock Titan
Investing.com Nigeria Direct company coverage

ClearPoint Neuro CEO Burnett sells $387,600 in company shares By Investing.com

ClearPoint Neuro CEO Joseph Burnett sold 20,000 shares of the company's common stock for $387,600 after exercising options. This transaction was part of a pre-arranged trading plan, and Burnett still holds a significant number of shares both directly and indirectly. The sale foll

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 11:10
Source
Investing.com Nigeria
Investing.com Direct company coverage

ClearPoint Neuro CEO Burnett sells $387,600 in company shares

Joseph Burnett, CEO and President of ClearPoint Neuro, Inc., sold 20,000 shares of the company’s common stock for $387,600 after exercising options. The transaction was pre-arranged, and Burnett still holds a significant number of shares both directly and indirectly. This sale fo

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 06:39
Source
Investing.com
TradingView Direct company coverage

Price to book forward of ClearPoint Neuro Inc. – NASDAQ:CLPT

This article provides financial information for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its price-to-book forward metric. It details where to find financial data, news, and other market-related information for the company on the TradingView platform.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 01:10
Source
TradingView
Investing.com Canada Direct company coverage

Form 4 Clearpoint Neuro Inc For: 1 July By Investing.com

This article announces the filing of Form 4 for Clearpoint Neuro Inc. on July 1st. It also includes general market data, popular news headlines, and an image indicating its source is Reuters.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 22:39
Source
Investing.com Canada
Stock Titan Direct company coverage

ClearPoint Neuro (CLPT) CEO exercises options and sells 20,000 shares under 10b5-1 plan

ClearPoint Neuro (CLPT) CEO Joseph Burnett exercised stock options to acquire 20,000 shares at $2.50 each and subsequently sold 20,000 shares at a weighted average price of $19.38. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 11,

Tone
Negative 39/100
Event
Market update
Published
01 Jul 2026 22:39
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of ClearPoint Neuro Inc. – NASDAQ:CLPT

This article provides financial data for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its "Price to sales forward" metric. It appears to be a stub or a data point from a financial platform like TradingView, indicating a value change for this specific financial r

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 17:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of ClearPoint Neuro Inc. – NASDAQ:CLPT

This article provides financial information for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its forward price-to-earnings ratio. It presents a table showing the period, value, change, and percentage change for this metric, noting that the data is "Made by human

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 01:10
Source
TradingView
Stock Titan Direct company coverage

Director sale notice, CLPT (NASDAQ: CLPT) — 20,000 shares via option exercise

This article reports that a director of ClearPoint Neuro, Inc. (NASDAQ: CLPT) has filed a Form 144 for the proposed sale of 20,000 shares of common stock through the exercise of stock options on June 29, 2026. The filing also details prior 10b5-1 sales by Joseph M. Burnett and th

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:43
Source
Stock Titan
Stock Traders Daily Direct company coverage

(CLPT) Movement as an Input in Quant Signal Sets

This article provides an in-depth quantitative analysis of Clearpoint Neuro, Inc. (NASDAQ: CLPT), highlighting strong near- and mid-term sentiment despite a weak long-term outlook. It details three AI-generated institutional trading strategies—Position Trading, Momentum Breakout,

Tone
Positive 66/100
Event
Guidance
Published
29 Jun 2026 00:42
Source
Stock Traders Daily
TradingView Direct company coverage

Enterprise value to EBIT forward of ClearPoint Neuro Inc. – NASDAQ:CLPT

This article from TradingView provides a financial metric, the enterprise value to EBIT forward, for ClearPoint Neuro Inc. (NASDAQ: CLPT). It indicates that the company's market is currently closed with no trades. The piece highlights a specific financial performance indicator fo

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 10:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of ClearPoint Neuro Inc. – NASDAQ:CLPT

This article provides financial information for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its enterprise value to revenue forward. The content appears to be a financial data snippet from TradingView, indicating that the stock market for CLPT is currently clos

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 00:41
Source
TradingView
TradingView Direct company coverage

ClearPoint Neuro, Inc. Actuals & Estimates (NASDAQ:CLPT)

This article provides an overview of ClearPoint Neuro Inc. (NASDAQ: CLPT) stock performance, forecasts, and financial data. It covers historical price movements, analyst price targets, upcoming earnings dates, and recent financial results including revenue, net income, and EBITDA

Tone
Positive 71/100
Event
Earnings
Published
26 Jun 2026 20:39
Source
TradingView
TradingView Direct company coverage

CLPT Forecast — Price Target — Prediction for 2027

The article provides a forecast for ClearPoint Neuro Inc. (CLPT) stock, including analyst price targets and predictions for 2027. It details the company's financial performance, stock volatility, market capitalization, earnings, revenue, and historical price data. The forecast in

Tone
Positive 66/100
Event
Earnings
Published
25 Jun 2026 14:40
Source
TradingView